Coloplast A/S Website

Coloplast A/S

CPSE-COLO B

Basic

  • Market Cap

    DKK 191.47B

  • EV

    DKK 215.09B

  • Shares Out

    224.84M

  • Revenue

    DKK 25.53B

  • Employees

    15,930

Margins

  • Gross

    67.13%

  • EBITDA

    30.69%

  • Operating

    27.49%

  • Pre-Tax

    24.67%

  • Net

    19.45%

  • FCF

    4.8%

Returns (5Yr Avg)

  • ROA

    24.04%

  • ROTA

    58.23%

  • ROE

    63.61%

  • ROCE

    60.75%

  • ROIC

    27.07%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    DKK 906.74

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    DKK 889M

  • Net Debt

    DKK 23.62B

  • Debt/Equity

    1.51

  • EBIT/Interest

    9.41

Growth (CAGR)

  • Rev 3Yr

    11.33%

  • Rev 5Yr

    8.24%

  • Rev 10Yr

    7.83%

  • Dil EPS 3Yr

    3.54%

  • Dil EPS 5Yr

    3.56%

  • Dil EPS 10Yr

    8.07%

  • Rev Fwd 2Yr

    9.46%

  • EBITDA Fwd 2Yr

    10.96%

  • EPS Fwd 2Yr

    10.16%

  • EPS LT Growth Est

    19%

Dividends

  • Yield

  • Payout

    93.69%

  • DPS

    DKK 21

  • DPS Growth 3Yr

    5.27%

  • DPS Growth 5Yr

    13.81%

  • DPS Growth 10Yr

    11.61%

  • DPS Growth Fwd 2Yr

    2.42%

Select a metric from the list below to chart it

Sep '14

Sep '15

Sep '16

Sep '17

Sep '18

Sep '19

Sep '20

Sep '21

Sep '22

Sep '23

LTM

Sep '24 (E)

Sep '25 (E)

Sep '26 (E)

Total Revenues

17,939

18,544

19,426

22,579

24,500

25,526

Total Revenues % Chg.

9.1%

3.4%

4.8%

16.2%

8.5%

6%

Cost of Goods Sold, Total

5,743

5,932

6,113

7,050

8,172

8,390

Gross Profit

12,196

12,612

13,313

15,529

16,328

17,136

Selling General & Admin Expenses, Total

5,963

6,079

6,247

7,802

8,633

9,253

Stock-Based Compensation

7

7

2

-2

-1

-1

R&D Expenses

692

708

755

866

872

901

Other Operating Expenses

-42

-29

-48

-56

-25

-34

Other Operating Expenses, Total

6,620

6,765

6,956

8,610

9,479

10,119

Operating Income

5,576

5,847

6,357

6,919

6,849

7,017

Interest Expense, Total

-6

-30

-25

-172

-638

-746

Interest And Investment Income

19

8

11

39

111

141

Net Interest Expenses

13

-22

-14

-133

-527

-605

Income (Loss) On Equity Invest.

Currency Exchange Gains (Loss)

2

-338

114

-134

-178

-51

Other Non Operating Income (Expenses)

-168

-32

-31

-66

-78

-4

EBT, Excl. Unusual Items

5,423

5,455

6,426

6,586

6,066

6,357

Restructuring Charges

-43

Merger & Related Restructuring Charges

-171

-118

-119

Gain (Loss) On Sale Of Assets

16

-4

-7

-3

-3

Insurance Settlements

Legal Settlements

-400

-200

-300

-200

-200

Other Unusual Items

32

11

11

19

280

263

EBT, Incl. Unusual Items

5,028

5,466

6,233

6,127

6,025

6,298

Income Tax Expense

1,155

1,269

1,408

1,421

1,242

1,333

Earnings From Continuing Operations

3,873

4,197

4,825

4,706

4,783

4,965

Net Income

3,873

4,197

4,825

4,706

4,783

4,965

Net Income to Common Incl Extra Items

3,873

4,197

4,825

4,706

4,783

4,965

Net Income to Common Excl. Extra Items

3,873

4,197

4,825

4,706

4,783

4,965

Total Shares Outstanding

212.4

212.7

212.8

212.3

224.7

224.8

Weighted Avg. Shares Outstanding

212.3

212.6

212.8

212.5

215.4

221.5

Weighted Avg. Shares Outstanding Dil

213.1

213.3

213.2

212.8

215.5

221.7

EPS

18.2

19.7

22.7

22.1

22.2

22.4

EPS Diluted

18.2

19.7

22.6

22.1

22.2

22.4

EBITDA

6,194

6,450

6,897

7,544

7,568

7,834

Effective Tax Rate

23%

23.2%

22.6%

23.2%

20.6%

21.2%